Articles related to IMMUNOTHERAPY

The first treatment for light-chain amyloidosis was approved by the FDA in 2021. Daratumumab-based regimens produce profound hematologic and organ responses, providing a new therapeutic foundation. Early detection, correct fibril typing, the challenges of the very advanced patient, and the lack of therapies to remove amyloid deposits are all being researched but remain elusive.

A total of 168 patients were randomly assigned to receive tumor-infiltrating lymphocytes (TILs) (84 patients) or ipilimumab (84 patients). The median progression-free survival in the TIL group was 7.2 months and 3.1 months in the ipilimumab group; 49% and 21% of the patients, respectively, had an objective response. The TIL group had a median overall survival of 25.8 months, while the ipilimumab group had a median overall survival of 18.9 months.

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.

Early triple-negative breast cancer patients who received pembrolizumab along with neoadjuvant chemotherapy had a significantly higher rate of pathological complete responses than those who received placebo along with neoadjuvant chemotherapy.

With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.

In this cohort study of 12,046 patients with cancer and COVID-19, it was discovered that the use of immunotherapy (IO) and other systemic anticancer therapies in combination with baseline immunosuppression was linked to worse outcomes and a higher incidence of cytokine storm in SARS-CoV-2-infected cancer patients.